Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Samsung Biologics (207940) – IBK Securities | US Operations · Plant 5 Ramp-up · Peptide Expansion / 2026-07-24 Research
  • [Research] SK hynix (000660 / SKHY) – Yuanta | Memory Pricing · Long-Term Contracts · Earnings Stability / 2026-04-23 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q3 2024 Earnings Presentation / 2024-10-29 IR Room
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Agentic AI · Server CPU · LPDDR / 2026-04-28 Research
  • [Research] Samsung SDI (006400) – Mirae Asset | Operating Profit Upgrades · Core Turnaround · Prismatic Competitiveness / 2026-07-31 Research
  • [Research] Samsung Electro-Mechanics (009150) – Kyobo Securities | AI Server Demand · High-Value Mix · Structural Profitability / 2026-07-31 Research
  • About Korea Equity Lens & Privacy Policy About
  • [Research] Samsung Electro-Mechanics (009150) – Mirae Asset Securities | Capacity Cannibalization · 1-Year LTA · Pricing Power / 2026-07-06 Research

[Research] Hanwha Ocean (042660) – Yuanta | Merchant Mix Improvement · CPSP Project Value · MASGA Catalysts / 2026-07-06

Posted on July 6, 2026August 22, 2026 By ksb220805@gmail.com

Brokerage : Yuanta Securities

Analyst : Yongmin Kim

Investment Rating : BUY (Maintained)

Target Price : KRW 179,000 (Maintained)

Core Momentum : Merchant earnings expansion driven by an increased revenue share of high-price FY24–25 orders, with medium-to-long-term valuation upside centered on the Canadian CPSP submarine tender outcome and 2H MASGA developments

📊 1. [Valuation & Key Financial Metrics]

  • Rating & Target Price: BUY Maintained, Target Price maintained at KRW 179,000 (Current Price: KRW 106,900 as of July 3, 2026; Upside potential: 67%)
  • 2Q26 Earnings Outlook: Projected Revenue of KRW 3.63 trillion (+10.2% YoY, +13.1% QoQ), Operating Profit of KRW 586.0 billion (+57.6% YoY, +32.8% QoQ, OPM 16.1%), and Net Profit of KRW 656.0 billion (+341.7% YoY, +31.1% QoQ), beating market consensus (operating profit of KRW 497.0 billion).
  • Key Forecast Financials (2025A → 2026F → 2027F):
    • Revenue: KRW 12.78 trillion → KRW 13.97 trillion → KRW 15.61 trillion
    • Operating Profit: KRW 1.17 trillion → KRW 2.18 trillion → KRW 2.47 trillion
    • Net Profit (Controlling): KRW 1.25 trillion → KRW 2.79 trillion → KRW 3.24 trillion
    • PER: 20.3x → 11.7x → 10.1x
    • PBR: 4.1x → 3.6x → 2.7x
    • ROE: 22.6% → 36.9% → 30.5%
    • EV/EBITDA: 21.6x → 14.3x → 11.3x

🚀 2. [Market Opportunities & Business Outlook]

  • Merchant Earnings Drivers: Results supported by a +7% QoQ increase in working days and favorable FX movements (estimated +KRW 78.0 billion in revenue, +KRW 27.0 billion in operating profit QoQ). Following the delivery of 9 units of FY22 orders in 1Q26, the revenue share of low-margin FY22 contracts dropped from 37% to 22%, while high-price FY24–25 vintages rose from 48% to 63%, offsetting the decline in the LNGC sales mix (71% → 62%).
  • Canadian CPSP Submarine Valuation: Securing the CPSP project is estimated to yield an average annual operating profit of KRW 500.0 billion during FY32–43F, and over KRW 300.0 billion annually in MRO profits from FY44F onward. Applying a 20x P/E multiple derives a project equity value of approximately KRW 8.0 trillion. Since CPSP value is unreflected in current valuations, temporary share price pullbacks in the event of competitor selection are viewed as buying opportunities.
  • Catalysts & Valuation Upside: While near-term share price volatility reflects CPSP tender uncertainty, fundamental downside remains well protected by sustained merchant earnings improvements and anticipated 2H MASGA-related defense developments even excluding CPSP.

📝 Editor’s Comment (Perspective)

The analyst views Hanwha Ocean as a defense and shipbuilding enterprise demonstrating robust commercial margin improvement through high-price order mix transition, while standing at a pivotal valuation inflection point governed by the Canadian CPSP submarine tender and upcoming US MASGA defense initiatives. This perspective focuses on the fundamental stability provided by commercial shipbuilding alongside the substantial long-term enterprise value potential tied to North American naval defense programs.

To evaluate whether this investment thesis continues to materialize, key verification points include confirmation of merchant OPM expansion in 2Q results driven by the growing share of FY24–25 high-price orders, the final contractor selection announcement for the Canadian CPSP submarine program, and concrete progress updates on US naval MRO/build partnerships under the MASGA framework in 2H. These factors can be tracked through upcoming quarterly earnings releases, official IR materials, regulatory filings, and periodic financial reports.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Shipbuilding, Research

Post navigation

Previous Post: [Research] SK hynix (000660 / SKHY) – Kyobo | Agentic AI · HBM Market Share · Earnings Growth / 2026-07-01
Next Post: [Research] Samsung Electro-Mechanics (009150) – Mirae Asset Securities | Capacity Cannibalization · 1-Year LTA · Pricing Power / 2026-07-06

Related Posts

  • [Research] LIG D&A (079550) – Hanwha Investment & Securities | 4Q25 Review · Ghost Robotics Impairment Cleared · Margin Expansion / 2026-02-23 Research
  • [Research] LIG D&A (079550) – Hana Securities | 1Q26 Earnings Beat · Backlog Re-rating · High-margin Follow-on Services / 2026-05-08 Research
  • [Research] LIG D&A (079550) – Kiwoom Securities | K-Defense Competitiveness · Pipeline Expansion · Rheinmetall JV / 2026-06-17 Research
  • [Research] Samsung SDI (006400) – Daishin Securities | Earlier Turnaround · North America ESS Expansion · LFP Order Pipeline / 2026-07-31 Research
  • [Research] Samsung SDI (006400) – Hana Securities | North America JV Resolution · ESS Line Conversion · Earnings Estimate Upgrades / 2026-08-12 Research
  • [Research] ABL Bio (298380) – Shinhan Securities | Sanofi Strategy · Clinical Differentiation · Platform Expansion / 2026-02-02 Research
  • [Research] Hanwha Ocean (042660) – SK Securities | Merchant Margin Growth · Offshore Order Requirements · Global Naval Pipeline / 2026-07-13 Research
  • [IR] SK hynix (000660 / SKHY) – Q3 2025 Earnings Presentation / 2025-10-29 IR Room
  • [Research] Alteogen (196170) – Shinhan Securities | Halozyme Patent Invalidated · Key Overhangs Materially Eased · Target Price Raised / 2026-05-14 Research
  • [Research] SK hynix (000660 / SKHY) – Hyundai Motor | Agentic AI · Memory Demand · Cycle Stability / 2026-05-13 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q4 2024 Earnings Presentation / 2025-01-24 IR Room
  • [Research] LIG D&A (079550) – Hana Securities | Complementing Patriot · Cheongung-II Cost Competitiveness · KRW 26.2T Backlog / 2026-03-03 Research
  • [Research] Celltrion (068270/KS) – SK Securities | New Portfolio Mix Expansion · Operating Leverage · H2 Product Launches / 2026-05-07 Research
  • [Research] Samsung SDI (006400) – iM Securities | Surging AIDC ESS Demand · US Regulatory Tailwinds · Valuation Assessment / 2026-04-29 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme